BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24166026)

  • 1. Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
    Kataoka K; Kanazawa A; Iwamoto S; Kato T; Nakajima A; Arimoto A
    World J Surg; 2014 Apr; 38(4):936-46. PubMed ID: 24166026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
    Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
    Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
    Power DG; Kemeny NE
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):251-64. PubMed ID: 20970353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
    Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
    Scoggins CR; Campbell ML; Landry CS; Slomiany BA; Woodall CE; McMasters KM; Martin RC
    Ann Surg Oncol; 2009 Jan; 16(1):35-41. PubMed ID: 18987915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.
    Tanaka K; Nojiri K; Kumamoto T; Takeda K; Endo I
    Eur J Surg Oncol; 2011 Apr; 37(4):336-43. PubMed ID: 21277151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
    Brandi G; Derenzini E; Falcone A; Masi G; Loupakis F; Pietrabissa A; Pinna AD; Ercolani G; Pantaleo MA; Di Girolamo S; Grazi GL; de Rosa F; Biasco G
    Clin Colorectal Cancer; 2013 Sep; 12(3):188-94. PubMed ID: 23773458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
    Adam R; Delvart V; Pascal G; Valeanu A; Castaing D; Azoulay D; Giacchetti S; Paule B; Kunstlinger F; Ghémard O; Levi F; Bismuth H
    Ann Surg; 2004 Oct; 240(4):644-57; discussion 657-8. PubMed ID: 15383792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
    Basso M; Dadduzio V; Ardito F; Lombardi P; Strippoli A; Vellone M; Orlandi A; Rossi S; Cerchiaro E; Cassano A; Giuliante F; Barone C
    Medicine (Baltimore); 2016 May; 95(20):e3722. PubMed ID: 27196492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
    Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
    Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK
    J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy.
    Nuzzo G; Giuliante F; Ardito F; Vellone M; Pozzo C; Cassano A; Giovannini I; Barone C
    J Gastrointest Surg; 2007 Mar; 11(3):318-24. PubMed ID: 17458605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
    Hokuto D; Nomi T; Yamato I; Yasuda S; Obara S; Yoshikawa T; Kawaguchi C; Yamada T; Kanehiro H; Nakajima Y
    J Surg Oncol; 2016 Dec; 114(8):959-965. PubMed ID: 27683191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
    Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
    Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and potential benefit of preoperative chemotherapy for colorectal liver metastasis (CLM): a single-centered retrospective study.
    Kataoka K; Kanazawa A; Nakajima A; Yamaguchi A; Arimoto A; Kohno Y
    Surg Today; 2013 Oct; 43(10):1154-61. PubMed ID: 23139049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
    Liu W; Wang K; Han Y; Liang JY; Li YH; Xing BC
    Eur J Surg Oncol; 2019 Nov; 45(11):2070-2077. PubMed ID: 31279595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
    Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
    Ayez N; van der Stok EP; Grünhagen DJ; Rothbarth J; van Meerten E; Eggermont AM; Verhoef C
    Eur J Surg Oncol; 2015 Jul; 41(7):859-67. PubMed ID: 25979624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.